Hypereosinophilia in patients with multiple sclerosis treated with natalizumab

Abbas, Mohamed; Lalive d'Epinay, Patrice; Chofflon, Michel; Simon, H-U; Chizzolini, Carlo; Ribi, Camillo

doi:10.1212/WNL.0b013e318233b391

Scientific article

Case report

English

Hypereosinophilia in patients with multiple sclerosis treated with natalizumab

ContributorsAbbas, Mohamed; Lalive d'Epinay, Patrice; Chofflon, Michel; Simon, H-U; Chizzolini, Carlo; Ribi, Camillo

Published inNeurology, vol. 77, no. 16, p. 1561-1564

Publication date2011

Abstract

To report asymptomatic hypereosinophilia as a potential side effect in patients treated with natalizumab, an α-4 integrin blocking agent.

Keywords

Adult
Antibodies, Monoclonal, Humanized/therapeutic use
Female
Humans
Hypereosinophilic Syndrome/complications/drug therapy
Middle Aged
Multiple Sclerosis/complications/drug therapy

Affiliation entities

Research groups

Citation (ISO format)

ABBAS, Mohamed et al. Hypereosinophilia in patients with multiple sclerosis treated with natalizumab. In: Neurology, 2011, vol. 77, n° 16, p. 1561–1564. doi: 10.1212/WNL.0b013e318233b391

Article (Published version)

Identifiers

PID : unige:25714
DOI : 10.1212/WNL.0b013e318233b391
PMID : 21975205

Journal ISSN0028-3878

692views

0downloads

Creation12/12/2012 17:16:00

First validation12/12/2012 17:16:00

Update time14/03/2023 19:58:25

Status update14/03/2023 19:58:25

Last indexation30/10/2024 08:32:05

Archive ouverte UNIGE

Hypereosinophilia in patients with multiple sclerosis treated with natalizumab

To report asymptomatic hypereosinophilia as a potential side effect in patients treated with natalizumab, an α-4 integrin blocking agent.

Technical informations